Trial Profile
Phase I trial of bromopyruvate (PSL-001) in patients with primary and/or metastatic liver cancer.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 18 Nov 2022
Price :
$35
*
At a glance
- Drugs Bromopyruvate (Primary)
- Indications Liver cancer; Liver metastases
- Focus Adverse reactions
- 26 Apr 2017 According to the PreScience media release, the company plans enrollment in this study in 2018.
- 25 Jul 2013 New trial record
- 24 Jul 2013 The US FDA has approved the IND application for phase I clinical evaluation of bromopyruvate and this trial is expected to be initiated in early 2014, according to a PreScience Labs media release.